Solabia Group

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Solabia Group - overview

Established

1972

Location

Pantin, -, France

Primary Industry

Biotechnology

About

Located in France, Solabia Group specializes in the development and production of high-quality ingredients for the cosmetics, pharmaceuticals, nutrition, biotechnology, and microbiological diagnostics sectors. Founded in 1972 and headquartered in Pantin, France, Solabia Group focuses on creating innovative ingredient solutions. The company has completed a total of 3 deals, with the most recent being a Secondary Buyout on May 7, 2025, where Astorg acquired a majority stake for EUR 1. 1 billion.


The founder, Livio Lima, has a history in entrepreneurial ventures, and the current CEO is Darren Fritschy. Solabia Group specializes in the development, production, and distribution of a diverse range of ingredients tailored for the cosmetics, pharmaceuticals, nutrition, biotechnology, and microbiological diagnostics sectors. Their core product offerings include natural actives, plant extracts, and various formulations such as peptones and hydrolysates, which cater to health and wellness applications. These products serve a wide array of end users, including manufacturers of cosmetics, dietary supplements, and pharmaceuticals, who rely on Solabia's innovative solutions to meet consumer demand for natural and sustainable ingredients.


The company's expertise extends across Europe, North America, and Asia, ensuring a broad client base that encompasses both industrial manufacturers and specialized research institutions. In 2023, Solabia Group reported a revenue of EUR 74,903,037. 60 and an EBITDA of EUR 22,929,729. 80.


The company generates revenue primarily through B2B transactions, focusing on high-quality, innovative ingredients for the cosmetics and pharmaceutical industries. Transactions typically occur through direct sales agreements and long-term partnerships, ensuring competitive pricing for bulk orders and tailored supply agreements aligned with clients' production cycles. With support from the recent acquisition deal, Solabia Group is poised to execute its growth strategy focused on international expansion and product innovation. The company plans to launch new products designed to meet emerging market needs, although specific release dates have yet to be announced.


Additionally, Solabia aims to expand its presence in new geographic regions, particularly targeting markets in Asia and North America by 2025, leveraging the resources from the EUR 1. 1 billion investment to support these initiatives.


Current Investors

TA Associates

Primary Industry

Biotechnology

Sub Industries

Beauty & Hygiene, Biopharmaceuticals, Molecular Chemicals

Website

www.solabia.com/

Verticals

Manufacturing

Company Stage

Mature - Buyout

Total Amount Raised

Subscriber access only

Solabia Group - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Add-onCompletedMibelle Biochemistry-
Add-on, Corporate Carve Out, Trade SaleCompletedSeqens SAS' Botanical Actives and In-Vitro Diagnostics activity-
Add-onCompletedXebios Diagnostics Group GmbH-
Secondary BuyoutAnnouncedSolabia Group-
Add-onCompletedPOLYMEREXPERT-

Displaying 1 - 5 of 10

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.